At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,225 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Global Comparative Observational Study In Rheumatoid Arthritis (RA) Patients Who Are Treated With A TNF Inhibitor Or Tocilizumab As The First Biologic Therapy
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 1,225 participants across 154 sites in 16 countries.
Detailed Summary
This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy. Data will be collected for 52 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Belgium, Colombia, Ecuador, Germany, Greece, Guatemala, Italy, Mexico, Panama, Portugal, Spain, Switzerland, Ukraine, United Kingdom, Uruguay
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedMar 2012
Primary CompletionFeb 2015
TodayJul 2026
First PostedMar 5, 2012
Enrollment StartFeb 1, 2012
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.3 years ago